Resistant Depression – Ketamine Infusion Trial Evaluation

This Phase I, dose escalation, safety study trial (n=24) evaluated the safety and tolerability of repeated ketamine infusions in adult patients with treatment-resistant depression (TRD).

Led by Dr Rupert McShane at Oxford Health NHS Foundation Trust, the trial aimed to explore the effectiveness of low-dose ketamine infusion in improving mood for individuals who had not responded to at least two adequate trials of antidepressants.

The study involved participants receiving Ketalar® (ketamine) intravenously over a 40-minute period, once weekly for three weeks in stage 1 and twice weekly for three weeks in stage 2.

The primary outcome measure was the safety and tolerability of repeated doses of ketamine, with secondary measures focusing on monitoring mood.

Recruitment began on 22/02/2010 and ended on 31/05/2012, with the overall study taking place within the same timeframe.

Topic Treatment-Resistant Depression Depression
Compound Ketamine
Country United Kingdom
Visit trial

Trial Details



Trial Number

Sponsors & Collaborators

University of Oxford
This company doesn't have a full profile yet, it is linked to a clinical trial.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.